Takashi Takeshita

Dr. Takashi Takeshita

Hokkaido University Hospital
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
ASAiko Sueta
Aiko Sueta
Yutaka YamamotoYutaka Yamamoto
Yutaka Yamamoto
MTMai Tomiguchi
Mai Tomiguchi
TTTakashi Takeshita
Takashi Takeshita
MYMutsuko Yamamoto-Ibusuki
Mutsuko Yamamoto-Ibusuki
HIHirotaka Iwase
Hirotaka Iwase
Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence

7 January 2008 in Cell Division
Verified
Journal Article
Open access
PDF file
WWWenwen Wu
Wenwen Wu
AKAyaka Koike
Ayaka Koike
TTTakashi Takeshita
Takashi Takeshita
TOTomohiko Ohta
Tomohiko Ohta
The basal-like breast cancer, a new category of breast cancer associated with poor prognosis and possibly unique chemosensitivity, is a current topic in the breast cancer field. Evidence from multiple sources strongly indicate that impairment of BRCA1 pathways is responsible for this phenotype, implying the importance of BRCA1 not only in familial breast cancers but also in sporadic cancers. BRCA1 acts as a hub protein that coordinates a diverse range of cellular pathways to maintain genomic stability. BRCA1 participates in multiple cellular supercomplexes to execute its tasks and, in most of the complexes, BRCA1 exists as a RING heterodimer with BARD1 to provide ubiquitin E3 ligase activity that is required for its tumor suppressor function. It was revealed recently that the BRCA1 RING finger is capable of catalyzing multiple types of ubiquitination depending upon the interacting E2, the ubiquitin carrier protein. BRCA1 may catalyze distinct ubiquitination on different substrates as the situation demands. On the other hand, in response to DNA double-strand breaks where BRCA1 plays its major role for homologous recombination repair, recent evidence showed that ubiquitination is a critical step to recruit BRCA1 to the damaged site through UIM (ubiquitin interacting motif) containing protein RAP80. Thus, ubiquitin and BRCA1 likely affect each other in many ways to perform cellular functions. Elucidation of this mechanism in relation to cell survival is now much anticipated because it could be a key to predict chemosensitivity of basal-like breast cancer.

1 December 2015 in Translational Research
Verified
Journal Article
Closed access
TTTakashi Takeshita
Takashi Takeshita
YYYutaka Yamamoto
Yutaka Yamamoto
MYMutsuko Yamamoto-Ibusuki
Mutsuko Yamamoto-Ibusuki
TIToko Inao
Toko Inao
ASAiko Sueta
Aiko Sueta
HIHirotaka Iwase
Hirotaka Iwase

14 June 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
TTTakashi Takeshita
Takashi Takeshita
YYYutaka Yamamoto
Yutaka Yamamoto
MYMutsuko Yamamoto-Ibusuki
Mutsuko Yamamoto-Ibusuki
MTMai Tomiguchi
Mai Tomiguchi
ASAiko Sueta
Aiko Sueta
HIHirotaka Iwase
Hirotaka Iwase
Background: The measurement of ESR1 and PIK3CA mutations in plasma cell-free DNA (cfDNA) has been studied as a non-invasive method to quickly assess and monitor endocrine therapy (ET) resistant metastatic breast cancer (MBC) patients.

19 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
TTTakashi Takeshita
Takashi Takeshita
YYYutaka Yamamoto
Yutaka Yamamoto
MYMutsuko Yamamoto-Ibusuki
Mutsuko Yamamoto-Ibusuki
TIToko Inao
Toko Inao
ASAiko Sueta
Aiko Sueta
HIHirotaka Iwase
Hirotaka Iwase
Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients

30 October 2015 in Cancer Science
Verified
Journal Article
Open access
PDF file
TTTakashi Takeshita
Takashi Takeshita
YYYutaka Yamamoto
Yutaka Yamamoto
MYMutsuko Yamamoto‐Ibusuki
Mutsuko Yamamoto‐Ibusuki
TIToko Inao
Toko Inao
ASAiko Sueta
Aiko Sueta
HIHirotaka Iwase
Hirotaka Iwase
PIK3CA is an oncogene that encodes the p110α component of phosphatidylinositol 3‐kinase (PI3K); it is the second most frequently mutated gene following the TP53 gene. In the clinical setting, PIK3CA mutations may have favorable prognostic value for hormone receptor‐positive breast cancer patients and, during the past few years, PIK3CA mutations of cell‐free DNA (cfDNA) have attracted attention as a potential noninvasive biomarker of cancer. However, there are few reports on the clinical implications of PIK3CA mutations for TNBC patients. We investigated the PIK3CA major mutation status of cfDNA as a noninvasive biomarker of cancer using droplet digital polymerase chain reaction (ddPCR), which has high level sensitivity and specificity for cancer mutation, in early‐stage 49 triple negative breast cancer (TNBC) patients. A total of 12 (24.4%) of 49 patients had PIK3CA mutations of cfDNA. In a median follow up of 54.4 months, the presence of PIK3CA mutations of cfDNA had significant impacts on relapse‐free survival (RFS; P = 0.0072) and breast cancer‐specific survival (BCSS; P = 0.016), according to the log‐lank test. In a Cox proportional hazards model, the presence of PIK3CA mutations of cfDNA had significant prognostic value in the univariate and multivariate analysis. Additionally, the presence of PIK3CA mutations of cfDNA was significantly correlated with positive androgen receptor phosphorylated form depending on PI3K signaling pathway (pAR) which is independent favorable prognostic factors of TNBC. We demonstrated that the presence of PIK3CA major mutations of cfDNA could be a discriminatory predictor of RFS and BCSS in early‐stage TNBC patients and it was associated with PI3K pathway‐dependent AR phosphorylation.